LobbyingAdneuris Therapeutics lobbying by quarter
Adneuris Therapeutics's latest lobbying report covers Q2 2026, at $15K. Its first report covers Q2 2026; the issues it reports most are Pharmacy.
Adneuris Therapeutics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $15K
- Last 2 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2026
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2026 | $15K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Pharmacy$15K · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- SENATE1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Mad Global Strategy | $15K | 1 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MIMI BRANIFF | Senate Energy Committee- Special Counsel; Senate Commerce Committee- Deputy Chief Counsel; Senate Appropriations Committee- Counsel; Senator Ted Stevens- Legislative Assistant | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/01for Q2 | Mad Global Strategy | $15K |
| 06/24for Q2 | Mad Global Strategy | Under $5,000 |